# Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study

> **NCT07093294** · — · RECRUITING · sponsor: **The Third Xiangya Hospital of Central South University** · enrollment: 60 (estimated)

## Conditions studied

- Crohn Disease (CD)
- Vedolizumab
- Intestinal Ultrasound
- Predictor

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07093294
- **Lead sponsor:** The Third Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-01
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-07-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07093294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07093294, "Value of IUS in Predicting Vedolizumab Efficacy and Assessing Transmural Healing in Early Crohn's Disease: A Multicenter, Prospective Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07093294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*